ClinicalTrials.gg
CompletedNCT04723602Updated Aug 3, 2022

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

A Phase 1 interventional study of cAd3-Marburg and cAd3-EBO-S in Ebola Virus Disease and Marburg Virus Disease, sponsored by Albert B. Sabin Vaccine Institute. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-03.

Sponsored by Albert B. Sabin Vaccine Institute · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Hemorrhagic Fever, Ebola with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Hemorrhagic Fever, Ebola · United States.

Enrollment
16th of 27
32 · median 48
Started
2021
the only one that year
Phase 1
20 of 28
1 open now
Registered
26th of 28
by date
Lead sponsor
1 of 28
Albert B. Sabin Vaccine Institute

Among the 28 studies in Hemorrhagic Fever, Ebola with a site in United States, this one is the 16th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2021, is one of 20 in phase 1, and was the 26th registered.

Hemorrhagic Fever, Ebola

104 studies on the registry are indexed under Hemorrhagic Fever, Ebola; 13 are open to participants now.

Browse Hemorrhagic Fever, Ebola studies →

Open to participants now

1 of the 28 studies in Hemorrhagic Fever, Ebola with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Hemorrhagic Fever, Ebola studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Hemorrhagic Fever, Ebola with a site in United States, or all of them as a file.
02

Study summary

Primary Objective:

  • To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10\^11 particle units (PU) to healthy adults.

Secondary Objectives:

  • To evaluate the antibody response to Monovalent Chimpanzee Adenoviral Vectored Filovirus Ebola-S (cAd3-EBO-S) and Monovalent Chimpanzee Adenoviral Vectored Filovirus (Marburg) (cAd3 Marburg) vaccines as assessed by antigen glycoprotein (GP) specific (enzyme-linked immunosorbent assay) ELISA
  • To collect sufficient post-vaccination plasma to support further development of filovirus assays
Read the detailed description

Primary Endpoints: Safety

Assessment of product safety will include clinical observation and monitoring of clinical chemistry and hematology parameters. Safety will be closely monitored after injection and evaluated through Day 99 and one additional safety follow-up telephone call on Day 181 (± 14 Days). The following parameters will be assessed:

  • Occurrence and severity of solicited local reactogenicity signs and symptoms for 7 days following the vaccination
  • Occurrence and severity of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination
  • Change from baseline for safety laboratory measures
  • Occurrence of adverse events of all severities through 28 days after vaccination
  • Occurrence of serious adverse events and new chronic medical conditions through the last safety follow up call at Day 181(± 14 days)

Secondary Endpoints :

  • Antibody levels against vaccines cAd3-EBO-S and cAd3 Marburg as measured by enzyme-linked immunosorbent assay (ELISA) on Day 1, 15, 22, 29, 36, 43, 50, 57 and 64
  • 20 Liters of plasma per vaccine group will be collected for the purpose of assay development
03

Conditions studied

  • Ebola Virus Disease
  • Marburg Virus Disease

Keywords

  • Coronavirus Disease
  • Creatine phosphokinase
  • Clinical Research Associate
  • Contract Research Organization
  • Division of AIDS
  • Disseminated Intravascular Coagulation
  • Diagnostic Lab of Oklahoma
  • Deoxyribonucleic Acid
  • Species Zaire Ebolavirus
  • Electronic Case Report Form
  • Ethylenediaminetetraacetic Acid
  • Ebola Hemorrhagic Fever
  • Enzyme-Linked Immunosorbent Assay
  • Food and Drug Administration
  • Ebola Virus Disease
  • Degrees Fahrenheit
  • Good Clinical Practices
  • Good Laboratory Practices
  • Grams
  • Glycoprotein
  • Government and Public Health Solutions
  • GlaxoSmithKline
  • Hemagglutinin
  • Hereditary Angioedema
  • Hepatitis B Virus
  • Hepatitis C Virus
  • Human immunodeficiency virus
  • Human T-cell Leukemia Lymphoma Virus
  • Investigator's Brochure
  • International Council for Harmonisation
  • International Committee on the Taxonomy of Viruses
  • Identification
  • Immunoglobulin G
  • Immunoglobulin M
  • Intramuscular(ly)
  • Investigational New Drug
  • Investigational product
  • Intravenous
  • Marburg Virus
  • Marburg Virus Disease
  • Marburg hemorrhagic fever
  • Milliliter
  • Millimeters of Mercury
  • Modified Vaccinia Ankara
  • Nucleic Acid Test
  • Non-Disclosure Agreement
  • Non-Human Primate
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • Nucleoprotein
  • Nonsteroidal Anti-Inflammatory Drug
  • Oklahoma Blood Institute
  • Office for Human Research Protection
  • Plasmapheresis Assessment Review Team
  • Plaque Forming Unit
  • Physical Exam
  • Principal Investigator
  • Post Injection Reactogenicity
  • Project Manager
  • Prothrombin Time
  • Partial Thromboplastin Time
  • Particle Units
  • Ravn Virus
  • Recombinant Human Adenovirus Serotype 5
  • Species Reston ebolavirus
  • Ribonucleic Acid
  • Rapid Plasma Regain
  • Reverse Transcription Polymerase Chain Reaction
  • Serious Adverse Event
  • Severe Acute Respiratory Syndrome Coronavirus 2
  • Statistical Analysis System
  • Schedule of Events
  • Standard Operating Procedure
  • Serum Separator Tube
  • Species Sudan Ebolavirus
  • Suspected, Unexpected and Serious Adverse Reaction
  • Species Taï Forest Ebolavirus
  • Technical Resources International, Inc
  • Universal Donor History Questionnaire
  • Upper Limit of Normal
  • Viral Particles
  • Vaccine Research Center
  • Vesicular Stomatitis Virus
  • Variant Creutzfeldt-Jakob Disease
  • White blood cell
  • World Health Organization
  • Western Institutional Review Board
  • Wild type
  • Zaire Ebola virus
  • Acquired Angioedema
  • Program, Inc.
  • Human adenovirus Serotype 5
  • Activities of Daily Living
  • Adverse Event
  • Acquired Immunodeficiency Syndrome
  • Alanine aminotransferase
  • Assessment of Understanding
  • Aspartate Aminotransferase
  • Biomedical Advanced Research and Development Authority
  • Species Bundibugyo ebolavirus
  • Blood Establishment Computer System
  • Body mass index
  • Blood Urea Nitrogen
  • Recombinant Chimpanzee Adenovirus Serotype 3
  • Recombinant Chimpanzee Adenovirus
  • Recombinant Chimpanzee Adenovirus Serotype 63
  • Complete blood count
  • Center for Disease Control and Prevention
  • Code of Federal Regulations
  • Confidence Interval
  • Centimeters
  • Type 3-Vectored Ebola virus Vaccine
  • Type 3-Vectored Ebola Sudan Vaccine
  • Type 3-Vectored Marburg Vaccine
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participant must be between 18-50 (inclusive) years of age;
  • Meet criteria for plasma donation*;
  • Available for clinic follow-up through Day 99 and one additional follow-up call on Day 181 (±14 days);
  • Agrees not to receive any vaccine from day of enrollment through Day 99;
  • Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process;
  • Agree to have photos taken of the vaccination site, if indicated ;
  • Willing to complete repeated plasmapheresis and other protocol requirements;
  • Must complete an Assessment of Understanding (AoU) by answering 9 out of 10 questions correctly at least once in 3 attempts;
  • Willing to donate blood for sample storage and future unspecified assay development;
  • Able to read (English) and willing to complete process;
  • In good general health without medical history, based on medical history, physical examination, vital signs and clinical laboratory results;
  • Physical examination and laboratory results without clinically significant findings and a (BMI) ≥ 17 and ≤ 35 within the 28 days prior to vaccination;
  • Laboratory Criteria within 28 days prior to vaccination (normal per testing laboratory) for: complete blood count (CBC) with differential count, (ALT), serum creatinine and total protein;
  • Serology screen negative for infectious diseases (, , , HTLV (Human T-cell leukemia lymphoma virus), Chagas disease, Syphilis;
  • Nucleic acid test (NAT) negative for Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), West Nile and Zika;
  • Negative antibody and reverse transcription polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome Covid 2 (SARS CoV-2) and free of current or prior symptoms concerning for COVID-19. Participants with a previous positive RT-PCR, at least 90 days prior to screening as reported in medical history, will not be excluded if they are antibody negative;
  • Female participant specific criteria:

    • Negative pregnancy serum test at screening and, negative urine pregnancy test before vaccination unless one of the following criteria is met:
  • At least 1 year ;
  • Surgically sterile;

    • Use of oral, implantable, transdermal or injectable for 21 days prior to and agrees to use through Day 181 ;
    • Use of another reliable form of contraception must be approved by the Investigator (e.g., double barrier method, Depo-Provera, intrauterine device, Norplant, oral contraceptives, contraceptive patches);
  • Male participants must agree:

    • Not to father a child or donate sperm through Day 181;
    • To use an effective means of birth control from at least 21 days prior to enrollment through Day 181 if assessed to be of .

Meet the criteria described in the AABB (formerly known as American Association of Blood Bank) and Uniform Donor History Questionnaire, with the exception of travel for malaria or Variant Creutzfeldt-Jakob Disease (vCJD) risk

Exclusion criteria

Exclusion Criteria:

  • COVID-19, Ebola or Marburg vaccine in a prior clinical trial or prior receipt of a cAd3 adenoviral vectored investigational vaccine;

    • Use of immunomodulators and systemic in daily doses of glucocorticoid equivalence > 20 mg of prednisolone in the last 90 days and for periods exceeding 10 days. Non-steroidal anti-inflammatory drugs [NSAIDS] are permitted. Participants that have used less than the stated glucocorticoid dose may still be excluded at the Investigator's discretion;
    • Blood products within 112 days prior to enrollment;
    • Investigational research agents within 90 days prior to enrollment;
    • Any licensed vaccine, inclusive of "live-attenuated" vaccine (e.g., oral polio, yellow fever, measles, etc.), killed, or subunit vaccine, within 28 days prior to enrollment;
    • Any experimental vaccines within 6 months prior to enrollment;
    • Current anti-tuberculosis prophylaxis or therapy;
  • Female participant specific criteria: woman who is pregnant, breast-feeding or planning to become pregnant through Day 181 (±14 days);
  • Unsatisfactory vein assessment for plasmapheresis via peripheral access (more details in Section 5.2.1)
  • History of any of the following conditions:

    • Serious adverse reactions to vaccines such as anaphylaxis, urticaria (hives), respiratory difficulty, angioedema, or abdominal pain;
    • Allergic reaction to in the study vaccine including gentamycin, neomycin or streptomycin;
    • Clinically significant disease or immunodeficiency;
    • Asthma that is not well controlled;
    • Positive result on a rapid plasma regain (RPR) test (A blood test for Syphilis);
    • Diabetes mellitus Type I or II;
    • Thyroid disease that is not well controlled ;
    • A history of hereditary angioedema (HAE), acquired angioedema (AAE), or idiopathic forms of angioedema;
    • Idiopathic urticaria within the last 1 year;
    • Hypertension that is not well controlled;
    • Bleeding disorder diagnosed by a doctor or use of anticoagulant medications such as, Coumadin, Eliquis, Pradaxa (e.g. factor deficiency, coagulopathy, or disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws;
    • A that is active, currently being treated, or not surgically cured (breast or prostate cancer successfully treated, with or without surgery is excluded; if diagnosed malignancy is 5 or more years prior to enrollment and cured with no ongoing treatment it will NOT be considered an exclusion);
    • Seizure in the past 3 years or treatment for seizure disorder in the past 3 years;
    • Asplenia or functional asplenia;
    • Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within five years prior to enrollment, history of a suicide plan or attempt;
    • Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a to protocol participation or impairs a participant's ability to give .
    • Abnormal laboratory results (per testing laboratory)
    • Positive COVID-19 symptom screen, SARS-CoV-2 RT-PCR, or SARS CoV-2 antibody test
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    cAd3-Marburg at 1 x 10^11 Particle Units (PU)

    A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10\^11 Particle Units (PU) vaccine.

    Biological: cAd3-Marburg

  • Active comparator
    cAd3-EBO-S at 1 x 10^11 PU vaccine

    A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10\^11 Particle Units (PU) vaccine.

    Biological: cAd3-EBO-S

Interventions

  • BiologicalcAd3-Marburg

    A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10\^11 Particle Units (PU) vaccine.

  • BiologicalcAd3-EBO-S

    A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10\^11 Particle Units (PU) vaccine.

06

What researchers measure

Primary outcomes

  1. Safety of Ebola and Marburg vaccines assessed by clinical observation.

    Safety of Ebola and Marburg vaccines, as seen in local reactogenicity signs and symptoms with diary questionnaire card.

    Time frame: 7 Days

  2. Safety of Ebola and Marburg vaccines assessed by clinical observation.

    Safety of Ebola and Marburg vaccines, as seen in systemic reactogenicity signs and symptoms with diary questionnaire card.

    Time frame: 7 Days

  3. Safety of Ebola and Marburg vaccines assessed by change from baseline in levels of Complete Blood Count (CBC).

    Safety of Ebola and Marburg vaccines assessed by change in levels of Complete Blood Count (CBC) w/differential count as laboratory measures of safety from baseline.

    Time frame: 6 months

  4. Safety of Ebola and Marburg vaccines assessed by change from baseline in levels of Creatinine.

    Safety of Ebola and Marburg vaccines assessed by change in levels of Creatinine as laboratory measures of safety from baseline.

    Time frame: 6 months

  5. Safety of Ebola and Marburg vaccines assessed by change from baseline in levels of Alanine Transaminase (ALT).

    Safety of Ebola and Marburg vaccines assessed by change in levels of Alanine Transaminase (ALT) as laboratory measures of safety from baseline.

    Time frame: 6 months

  6. Safety of Ebola and Marburg vaccines assessed by adverse experiences.

    Safety of Ebola and Marburg vaccines assessed by adverse events of all severities (Mild, moderate, and severe)

    Time frame: 28 days

  7. Safety of Ebola and Marburg vaccines assessed by serious adverse experiences.

    Safety of Ebola and Marburg vaccines assessed by serious adverse events of all severities (Mild, moderate, and severe)

    Time frame: 6 months

Secondary outcomes

  1. Evaluation of antibody response to cAd3-EBO-S and cAd3 Marburg vaccines

    Immunogenicity of the Ebola and Marburg vaccines as measured by antigen GP-specific ELISA

    Time frame: Measured at Day 1, 15, 22, 29, 36, 43, 50, 57, and 64

  2. Collection of sufficient post-vaccination plasma to support further development of filovirus assays.

    20 L of plasma per vaccine group (N=2) will be collected for the purpose of assay development. 800 mL of plasma will be collected at Day 29. Thereafter, plasma collections will be up to approximately 600 mL. Participants may donate up to 6 total times and all collections will be done within the limits of the FDA approved instructions for use for the Fenwal Alyx collection device.

    Time frame: May be collected at Day 29, 36, 43, 50, 57 and/or 64

07

Study locations

1 site
  • Oklahoma Blood Institute (OBI)
    Oklahoma City, Oklahoma 73104, United States
08

References and documents

Publications

  • Sanchez A, Kiley MP, Klenk HD, Feldmann H. Sequence analysis of the Marburg virus nucleoprotein gene: comparison to Ebola virus and other non-segmented negative-strand RNA viruses. J Gen Virol. 1992 Feb;73 ( Pt 2):347-57. doi: 10.1099/0022-1317-73-2-347. PubMed 1538192 ↗
  • Sanchez A, Kiley MP, Holloway BP, Auperin DD. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res. 1993 Sep;29(3):215-40. doi: 10.1016/0168-1702(93)90063-s. PubMed 8237108 ↗
  • Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med. 2004 Dec;10(12 Suppl):S110-21. doi: 10.1038/nm1142. PubMed 15577929 ↗
  • Hensley LE, Jones SM, Feldmann H, Jahrling PB, Geisbert TW. Ebola and Marburg viruses: pathogenesis and development of countermeasures. Curr Mol Med. 2005 Dec;5(8):761-72. doi: 10.2174/156652405774962344. PubMed 16375711 ↗
  • Ledgerwood JE, DeZure AD, Stanley DA, Coates EE, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, Sitar S, Gordon IJ, Plummer SA, Holman LA, Hendel CS, Yamshchikov G, Roman F, Nicosia A, Colloca S, Cortese R, Bailer RT, Schwartz RM, Roederer M, Mascola JR, Koup RA, Sullivan NJ, Graham BS; VRC 207 Study Team. Chimpanzee Adenovirus Vector Ebola Vaccine. N Engl J Med. 2017 Mar 9;376(10):928-938. doi: 10.1056/NEJMoa1410863. Epub 2014 Nov 26. PubMed 25426834 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Dec 2021, 11 months.

Of 16 phase 1 interventional studies under Hemorrhagic Fever, Ebola, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2020
First posted
Jan 26, 2021
StartActual
Jan 6, 2021
Primary completionActual
Dec 14, 2021
CompletionActual
Dec 14, 2021
Last update
Aug 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04723602
Lead sponsor
Albert B. Sabin Vaccine Institute
Collaborators
ICON plc, Oklahoma Blood Institute
Responsible party
Sponsor
First posted
Jan 26, 2021
Start date
Jan 6, 2021
Primary completion
Dec 14, 2021
Completion
Dec 14, 2021
Last update
Aug 3, 2022

Study contacts

Roxana Rustomjee, MBChB
study chair · The Albert B. Sabin Vaccine Institute
Michael Stevenson, MD
principal investigator · Oklahoma Blood Institute
David Hoover, MD
study director · ICON plc
Tuan Le, MD
principal investigator · Oklahoma Blood Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion